Published in Br J Cancer on January 08, 2013
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28
Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov (2013) 2.59
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell (2015) 1.77
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol (2014) 1.34
High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol (2013) 1.31
Machine Learning methods for Quantitative Radiomic Biomarkers. Sci Rep (2015) 1.19
Fast and scalable inference of multi-sample cancer lineages. Genome Biol (2015) 1.13
Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer. BMC Syst Biol (2013) 1.12
Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12
The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol (2016) 1.11
The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience (2014) 1.08
Therapeutic strategies targeting cancer stem cells. Cancer Sci (2015) 1.07
Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06
Meta-analysis of expression of l(3)mbt tumor-associated germline genes supports the model that a soma-to-germline transition is a hallmark of human cancers. Int J Cancer (2013) 1.05
Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review. PLoS One (2014) 1.00
The cancer cell map initiative: defining the hallmark networks of cancer. Mol Cell (2015) 0.94
Optical metabolic imaging quantifies heterogeneous cell populations. Biomed Opt Express (2015) 0.93
Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response. Anal Chem (2014) 0.92
A river model to map convergent cancer evolution and guide therapy in RCC. Nat Rev Urol (2015) 0.91
Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res (2014) 0.91
Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev (2014) 0.90
Evaluation of breast cancer using intravoxel incoherent motion (IVIM) histogram analysis: comparison with malignant status, histological subtype, and molecular prognostic factors. Eur Radiol (2015) 0.90
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
Quantitative proteomic analysis of meningiomas for the identification of surrogate protein markers. Sci Rep (2014) 0.89
Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq. PLoS One (2015) 0.88
In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. Oncotarget (2013) 0.87
Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst Pharmacol (2014) 0.87
Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol Ther (2014) 0.86
Competing views on cancer. J Biosci (2014) 0.86
Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. Med Res Arch (2016) 0.86
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res (2015) 0.85
Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer. Front Oncol (2015) 0.85
Applications and limitations of radiomics. Phys Med Biol (2016) 0.85
BreakSeek: a breakpoint-based algorithm for full spectral range INDEL detection. Nucleic Acids Res (2015) 0.84
Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol (2013) 0.84
Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. Transl Oncol (2015) 0.83
Tumour Cell Heterogeneity. F1000Res (2016) 0.83
Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol (2014) 0.83
Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Sci Rep (2016) 0.83
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer. Proc Natl Acad Sci U S A (2016) 0.82
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell (2016) 0.81
In vivo molecular imaging of cancer stem cells. Am J Nucl Med Mol Imaging (2014) 0.81
A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses. Oncogene (2015) 0.79
Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition. J Med Chem (2014) 0.79
Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proc Natl Acad Sci U S A (2016) 0.79
Multiple region whole-exome sequencing reveals dramatically evolving intratumor genomic heterogeneity in esophageal squamous cell carcinoma. Oncogenesis (2015) 0.79
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting. Adv Mater (2015) 0.79
Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today (2016) 0.79
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat Commun (2016) 0.79
A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer. PLoS One (2016) 0.78
Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol (2016) 0.78
Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer (2017) 0.78
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Design and applications of bispecific heterodimers: molecular imaging and beyond. Mol Pharm (2014) 0.78
Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. J Natl Compr Canc Netw (2015) 0.78
Derivation of a fifteen gene prognostic panel for six cancers. Sci Rep (2015) 0.78
ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles. BMC Bioinformatics (2015) 0.78
Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer (2013) 0.78
Integrative gene set analysis of multi-platform data with sample heterogeneity. Bioinformatics (2014) 0.78
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med (2015) 0.78
miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells. Cell Cycle (2014) 0.77
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer. PLoS One (2016) 0.77
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist (2016) 0.77
Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways. Cancer Genomics Proteomics (2016) 0.77
Tumor Evolution: Linear, Branching, Neutral or Punctuated? Biochim Biophys Acta (2017) 0.77
Nanomaterial-Enabled Cancer Therapy. Mol Ther (2017) 0.77
Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res (2016) 0.76
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci (2016) 0.76
Inferring models of multiscale copy number evolution for single-tumor phylogenetics. Bioinformatics (2015) 0.76
Emergent properties of a computational model of tumour growth. PeerJ (2016) 0.76
The Quest for Targets Executing MYC-Dependent Cell Transformation. Front Oncol (2016) 0.76
Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity. Acta Naturae (2017) 0.75
Heterogeneity of KRAS Mutation Status in Rectal Cancer. PLoS One (2016) 0.75
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn (2016) 0.75
Mining the Dynamic Genome: A Method for Identifying Multiple Disease Signatures Using Quantitative RNA Expression Analysis of a Single Blood Sample. Microarrays (Basel) (2015) 0.75
Cell injury, retrodifferentiation and the cancer treatment paradox. Tumour Biol (2015) 0.75
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Ann Oncol (2016) 0.75
IDICAP: A Novel Tool for Integrating Drug Intervention Based on Cancer Panel. J Pers Med (2016) 0.75
FISHtrees 3.0: Tumor Phylogenetics Using a Ploidy Probe. PLoS One (2016) 0.75
Rational design of non-resistant targeted cancer therapies. Sci Rep (2017) 0.75
CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget (2016) 0.75
Pathway-Informed Classification System (PICS) for Cancer Analysis Using Gene Expression Data. Cancer Inform (2016) 0.75
Clonal cooperativity in heterogenous cancers. Semin Cell Dev Biol (2016) 0.75
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem (2016) 0.75
The evolution of tumour phylogenetics: principles and practice. Nat Rev Genet (2017) 0.75
Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer. Int J Mol Sci (2017) 0.75
KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer. BMC Cancer (2017) 0.75
Microwell arrays reveal cellular heterogeneity during the clonal expansion of transformed human cells. Technology (Singap World Sci) (2015) 0.75
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud (2016) 0.75
Mapping mitochondrial heteroplasmy in a Leydig tumor by laser capture micro-dissection and cycling temperature capillary electrophoresis. BMC Clin Pathol (2017) 0.75
Gene Expression in Single Cells Isolated from the CWR-R1 Prostate Cancer Cell Line and Human Prostate Tissue Based on the Side Population Phenotype. Single Cell Biol (2016) 0.75
Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types. Assay Drug Dev Technol (2016) 0.75
Imaging and therapeutic applications of zinc(ii)-dipicolylamine molecular probes for anionic biomembranes. Chem Commun (Camb) (2016) 0.75
Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep (2016) 0.75
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med (2016) 0.75
Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research. J Transl Med (2016) 0.75
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother (2013) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
The clonal evolution of tumor cell populations. Science (1976) 24.39
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Tumor heterogeneity. Cancer Res (1984) 6.17
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62
Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 4.19
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
Chromosomal instability confers intrinsic multidrug resistance. Cancer Res (2011) 3.70
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood (2012) 3.63
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.91
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (1992) 2.80
Heterogeneity maintenance in glioblastoma: a social network. Cancer Res (2011) 2.66
Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep (2012) 2.28
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res (2011) 2.05
Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat (2006) 2.04
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Tracing the tumor lineage. Mol Oncol (2010) 1.56
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer (2011) 1.41
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38
Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol (2012) 1.33
Cancer in light of experimental evolution. Curr Biol (2012) 1.17
Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One (2012) 1.16
Evolutionary dynamics in cancer therapy. Mol Pharm (2011) 1.03
Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications. J Pathol (2011) 0.90
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 4.19
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Triple-negative breast cancer--current status and future directions. Ann Oncol (2009) 2.78
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol (2011) 1.64
Accuracy of amplitude-integrated electroencephalography in the prediction of neurodevelopmental outcome in asphyxiated infants receiving hypothermia treatment. Acta Paediatr (2013) 1.58
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J (1999) 1.30
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol (2006) 1.25
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer (2005) 1.18
Atomic order and cluster energetics of a 17 wt% Si-based glass versus the liquid phase. J Phys Condens Matter (2013) 1.17
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist (2001) 1.17
RMCSANS--modelling the inter-particle term of small angle scattering data via the reverse Monte Carlo method. J Phys Condens Matter (2010) 1.08
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol (2008) 1.07
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg (2001) 1.06
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer (2012) 1.05
The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.01
Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res (2001) 1.00
Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature. J Urol (1998) 0.98
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol (2007) 0.97
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. Ann Oncol (2012) 0.95
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol (2007) 0.95
Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle (2005) 0.95
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J (2001) 0.92
Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat (2004) 0.92
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer (2013) 0.90
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.90
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg (2008) 0.87
Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance. Breast (2001) 0.86
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res (1998) 0.85
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma (1998) 0.85
Promises and caveats of in silico biomarker discovery. Br J Cancer (2008) 0.83
Percutaneous endoscopic gastrostomy at the time of tumour resection in advanced oral cancer. Oral Oncol (2000) 0.83
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer (2008) 0.81
Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer (1999) 0.80
Pituitary corticotrophs proliferate temporarily after adrenalectomy. Histochemistry (1991) 0.79
Nanometer range correlations between molecular orientations in liquids of molecules with perfect tetrahedral shape: CCl(4), SiCl(4), GeCl(4), and SnCl(4). J Chem Phys (2009) 0.79
Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res (2000) 0.79
Hydration structure in concentrated aqueous lithium chloride solutions: a reverse Monte Carlo based combination of molecular dynamics simulations and diffraction data. J Chem Phys (2012) 0.78
On the structure of aqueous LiCl solutions. J Chem Phys (2005) 0.78
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer (2010) 0.76
Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene (2017) 0.75
RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress. Oncogene (2016) 0.75
The origin of diffuse scattering in crystalline carbon tetraiodide. J Phys Condens Matter (2013) 0.75
Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets. Breast Cancer Res Treat (2014) 0.75
Development of the time-dependent reverse Monte Carlo simulation, RMCt. J Phys Condens Matter (2007) 0.75
Structural disorder in lithium lanthanum titanate: the basis of superionic conduction. J Phys Condens Matter (2010) 0.75
Acidic properties of aqueous phosphoric acid solutions: a microscopic view. J Phys Condens Matter (2013) 0.75
IFN-gamma down-regulates MHC expression and antigen processing in a human B cell line. J Immunol (1999) 0.75
Orientational correlations in liquid, supercritical and gaseous carbon dioxide. J Phys Condens Matter (2007) 0.75
Polyanions in molten KPb-a paradox explained? J Phys Condens Matter (2007) 0.75
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Invest New Drugs (2013) 0.75
The amphetamines. Med J Aust (1967) 0.75
Adjuvant therapy for breast cancer. Minerva Ginecol (2005) 0.75